Trihexyphenidyl (THP, benzhexol, trihex, marketed as Artane and others) is an
antispasmodic drug used to treat stiffness, tremors, spasms, and poor muscle control. It is an agent of the
antimuscarinic class and is often used in
management of Parkinson's disease. It was approved by the
FDA for the treatment of Parkinson's in the US in 2003.[2][3]
The drug cannot cure Parkinson's disease, but may provide substantial alleviation of symptoms. An estimated 50–75% of people with Parkinson's disease will react positively and experience a 20–30% symptomatic improvement. To increase therapeutic activity, trihexyphenidyl is often given concomitantly with
levodopa or other
antimuscarinic or
antihistaminic (e.g.
diphenhydramine) agents.
Combination therapy with
dopamine agonists such as
cabergoline is also possible. This is often termed a 'multidimensional approach'. It has also been prescribed for
essential tremor and
akathisia.[6][7]
Contraindications
Contraindications include according to the Therapeutic Goods Administration Australia from 2022:[8]
Ileus (disruption of the normal propulsive ability of the intestine)
Caution: People with obstructive diseases of the urogenital tract, people with a known history of seizures and those with potentially dangerous
tachycardia
People under 18 years of age should not be treated due to a lack of clinical experience.
People should allow a period to adjust to the dose when first starting trihexyphenidyl and when the dose has been increased or added to a regimen with other drugs because acute somnolence and accumulated fatigue can make it particularly dangerous to operate an automobile, heavy machinery etc.
Adverse effects
Dose-dependent
side effects are frequent, but typically lessen over time as the body adapts to the medication. All of the following symptoms considered, Artane has been shown to dramatically and consistently improve neurologic defects in people aged 16–86 over the course of five years.[9] People who are older or who have psychiatric conditions may become confused or develop
delirium. Side effects include but are not limited to:[10]
Central nervous system:
drowsiness,
vertigo,
headache, and
dizziness are frequent. With high doses nervousness, agitation,
anxiety, delirium, and confusion are noted. Trihexyphenidyl may be abused due to a short acting mood-elevating and euphoric effect. The normal sleep architecture may be altered (
REM sleep depression). Trihexyphenidyl may lower the seizure-threshold.
Peripheral side effects: dry mouth, impaired sweating, abdominal discomfort,
nausea, and
constipation are frequent.
Tachycardia or heart palpitations (fast heart rate) may be noted. Allergic reactions are rare, but may occur. Many of these peripheral symptoms, especially considering an acute increase in anxiety with various physical complaints, as well as evidence of orthostatic hypotension and tachycardia are indicative of
withdrawal, especially in people with psychiatric conditions [11]
Eyes: trihexyphenidyl causes
mydriasis with or without
photophobia. It may precipitate narrow angle glaucoma or cause blurred vision.
Tolerance may develop during therapy which requires dose adjustments.
Striated musculature and weight gain.
Trihexyphenidyl is a
pregnancy category C drug. It is advised to only use with caution if benefits outweigh risks.[12]
Trihexyphenidyl (THP) and other antiparkinsonian drugs are known to be substances of abuse. This is true both in abusers of other substances and in chronic schizophrenics, the latter being infrequent abusers of other drugs. Trihexyphenidyl mimics an atropine intoxication with mydriasis, dryness of mucous membranes, red face, atonic states of bowels and bladder, and
hyperthermia in high doses. Central consequences are agitation, confusion, and hallucinations. An untreated overdose may be fatal, particularly in children. Premortal signs are respiratory depression and cardiac arrest. A specific antagonist is
physostigmine which combines a peripheral and a central action.
Carbachol can be used to treat atonic bowel and bladder. The vital functions should be monitored and stabilized. It may be necessary to treat hyperthermia with cooling blankets. Clinical case reports have repeatedly shown overdose of trihexyphenidyl alongside other substances.
The exact mechanism of action in parkinsonian syndromes is not precisely understood, but it is known that trihexyphenidyl blocks efferent impulses in parasympathetically innervated structures like smooth muscles (spasmolytic activity), salivary glands, and eyes (
mydriasis). In higher doses direct central inhibition of cerebral motor centers may contribute. In very high doses central toxicity as seen in
atropine overdose is noted. It binds to the
M1 muscarinic receptor[13] and possibly the
dopamine receptor.[which?][14] Trihexyphenidyl is rapidly absorbed from the
gastrointestinal tract. The onset of action is within 1 hour after oral dosing. The peak activity is noted after 2 to 3 hours.[15] The duration of action of one single dose is 6 to 12 hours in a dose dependent manner. It is excreted in the urine, probably as unchanged drug. More precise data in animals and humans have so far not been determined.[16][17]
History
Trihexyphenidyl has been clinically relevant in trials pertaining to Parkinson's disease since 1949.[18]
In the US, the FDA approved Artane, or its generic form Trihexyphenidyl HCL, only on June 25, 2003 for the clinical use of all types of parkinsonism.[19]
Society and culture
Recreational use
The neurologist
Oliver Sacks reported using the drug recreationally in the 1960s.[20] He recalled taking "a large dose" knowing full well the drug was intended for people with Parkinson's. More recounts of Dr. Sacks' experiences — including experimentation with
mescaline,
psilocybin,
LSD, and probably
DMT[21] — have been compared in his book Hallucinations.
During the 1970s, trihexyphenidyl (trade name Parkan) was the most popular recreationally used prescription drug in
Hungary.[22]
In a 2008 news report, trihexyphenidyl was seen to be used for recreational purposes among Iraqi soldiers and police, among other prescription drugs. The report states that the drugs were taken to relieve
combat stress reaction.[23] Although that may be the case for some, others used Artane as a substitute or more intense version of LSD. This was especially prevalent in the 1960s, according to a report in "The New Yorker". Similarly to those in Iraqi forces, some of the appeal was that the individual may retain partial control while under the influence.[24]
Chemistry
Trihexyphenidyl can be synthesized in two ways, one linear and one convergent synthesis.
In the first way, the initial 2-(1-piperidino)propiophenone is synthesized in turn by the aminomethylation of
acetophenone using
paraformaldehyde and
piperidine in a
Mannich reaction. In the second step the 2-(1-piperidino)propiophenone is reacted with cyclohexylmagnesium bromide in a
Grignard reaction.[25]
^World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization.
hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
^Harris MK, Shneyder N, Borazanci A, Korniychuk E, Kelley RE, Minagar A (March 2009). "Movement disorders". The Medical Clinics of North America. Common Neurologic Disorders. 93 (2): 371–88, viii.
doi:
10.1016/j.mcna.2008.09.002.
PMID19272514.
^Inada T (December 2017). "[Drug-Induced Akathisia]". Brain and Nerve = Shinkei Kenkyu No Shinpo. 69 (12): 1417–1424.
doi:
10.11477/mf.1416200927.
PMID29282345.
^Doshay LJ, Constable K, Zier A (April 1954). "Five year follow-up of treatment with trihexyphenidyl (artane); outcome in four hundred eleven cases of paralysis agitans". Journal of the American Medical Association. 154 (16): 1334–6.
doi:
10.1001/jama.1954.02940500014005.
PMID13151847.
^McEvoy GK, ed. (2006). "Trihexyphenidyl". AHFS drug information. Bethesda, MD: American Society of Health-System Pharmacists. p. 1256.
^Doshay LJ, Constable K (August 1949). "Artane therapy for parkinsonism; a preliminary study of results in 117 cases". Journal of the American Medical Association. 140 (17): 1317–22.
doi:
10.1001/jama.1949.02900520003002.
PMID18137284.
^Sacks O (20 August 2012).
"Altered States". The New Yorker. Condé Nast. Retrieved 7 May 2017.
^Weiss MJ, O'Donoghue MD (September 1957). "Synthesis of Certain 3-Hydroxy-3-phenylpropylsulfonium Salts. Sulfonium Analogs of Artane (Trihexyphenidyl) and Pathilon (Tridihexethyl Iodide)". Journal of the American Chemical Society. 79 (17): 4771–6.
doi:
10.1021/ja01574a048.
^Rote Liste Service GmbH (Hrsg.) (2017). Rote Liste 2017 – Arzneimittelverzeichnis für Deutschland (einschließlich EU-Zulassungen und bestimmter Medizinprodukte). Vol. 57. Frankfurt/Main: Rote Liste Service GmbH. p. 224.
ISBN978-3-946057-10-9.
^Sanger TD, Bastian A, Brunstrom J, Damiano D, Delgado M, Dure L, et al. (May 2007). "Prospective open-label clinical trial of trihexyphenidyl in children with secondary dystonia due to cerebral palsy". Journal of Child Neurology. 22 (5): 530–7.
doi:
10.1177/0883073807302601.
PMID17690057.
S2CID73087776.
^Tarnopolsky M, Alshahoumi R (November 2015). ""Complex I Deficiency". In Saneto R, Parikh S, Cohen BH (eds.). Mitochondrial Case Studies: Underlying Mechanisms and Diagnosis. Academic Press. pp. 257–64.
ISBN978-0-12-801149-2.